Uncategorized
Some challenges remain in the management of DME
There can be no doubt that anti-VEGF agents have revolutionized the management of diabetic macular edema. Whether we use monoclonal antibodies as in bevacizumab, antibody fragments as in ranibizumab or fusion proteins as in aflibercept to block VEGF, the randomized controlled multicenter international clinical trials have shown superior treatment outcomes in DME compared with laser or steroids. At 1 year the visual acuity gain is around eight letters, and this is maintained into the second year. Good glycemic control, blood pressure and lipid control are also important in the prevention (Read more...)